ICU Medical (ICUI) Set to Announce Earnings on Tuesday

ICU Medical (NASDAQ:ICUI) is scheduled to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect ICU Medical to post earnings of $0.84 per share for the quarter. ICU Medical has set its FY24 guidance at $4.40-5.10 EPS and its FY 2024 guidance at 4.400-5.100 EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.39. ICU Medical had a positive return on equity of 6.35% and a negative net margin of 1.31%. The firm had revenue of $587.86 million during the quarter, compared to analyst estimates of $564.77 million. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Stock Up 0.2 %

Shares of NASDAQ ICUI traded up $0.15 during mid-day trading on Tuesday, hitting $97.55. The stock had a trading volume of 15,780 shares, compared to its average volume of 246,571. The business has a 50 day moving average price of $101.40 and a two-hundred day moving average price of $97.52. ICU Medical has a 1 year low of $78.28 and a 1 year high of $212.43. The company has a quick ratio of 1.06, a current ratio of 2.53 and a debt-to-equity ratio of 0.74.

Wall Street Analysts Forecast Growth

Separately, KeyCorp upped their price objective on shares of ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and a consensus price target of $123.00.

Insider Activity

In related news, COO Christian B. Voigtlander sold 13,603 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $107.19, for a total value of $1,458,105.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other ICU Medical news, VP Daniel Woolson sold 791 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $98.27, for a total transaction of $77,731.57. Following the transaction, the vice president now owns 13,980 shares in the company, valued at approximately $1,373,814.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Christian B. Voigtlander sold 13,603 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $107.19, for a total value of $1,458,105.57. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,262 shares of company stock valued at $2,545,532. Company insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.